PEGylated dendritic nanoarchitechture improves mean survival time of BDF1 mice bearing myelogenous k -562 leukemia

Abstract

ObjectiveTo developing and exploring the use of PEGylated poly (propylene imine) dendritic architecture for the delivery of an anti leukemic activity of Prednisolone. MethodsFor this study, PEGylated poly (propylene imine) dendritic architecture was synthesized and loaded with Prednisolone and targeted to the ascetic form of myelogenous leukemia k-562 cellines in hybrid mice BDF1, was used as tumor model. The antileukemic activity was assessed by use of the criterion T/C %, where T was the mean survival time (MST, days) of the drug treated mice, bearing k-562 leukemia and C – the mean survival time (MST, days) of untreated control animals, bearing the same leukemia cellines. ResultsAn antileukemic activity of the studied Prednisolone loaded PEGylated Polypropyleneimine (PPI) dendrimer was found to have increasing the mean survival time of the k-562 myelogenous leukemia cellines bearing BDF1 mice. The criterion “increase of life span” (ILS%) reached maximally 270.1% for the drug loaded dendrimer. ConclusionThe studied dendrimer with Prednisolone showed lower toxicity with improved antileukemic activity in comparison with free Prednisolone. The further experiments in this field are in progress, aiming to design better dendritic formulations, with potential clinical use